Subscribe To
GILD / Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?
GILD News
By Business Wire
November 3, 2023
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America more_horizontal
By Zacks Investment Research
October 30, 2023
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day. more_horizontal
By Zacks Investment Research
October 30, 2023
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 resul more_horizontal
By Zacks Investment Research
October 24, 2023
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close. more_horizontal
By InvestorPlace
October 20, 2023
7 Healthcare Stocks to invest in for a Healthy Future
One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant develop more_horizontal
By Zacks Investment Research
October 19, 2023
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). Bu more_horizontal
By Market Watch
October 17, 2023
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs
Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with more_horizontal
By Seeking Alpha
October 15, 2023
Gilead Sciences Stock Is Cheap, With Broad Pipeline
Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis more_horizontal